Table 1.
Clinical Factors
| All | β2M | MHC Class I | MHC Class II | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | (n=103) | Dec/Neg (n=86) | Pos (n=17) | P | Dec/Neg (n=85) | Pos (n=18) | P | Dec/Neg (n=69) | Pos (n=34) | P | |
|
| |||||||||||
| Age - yr | Median (range) | 30 (18–69) | 29 (18–69) | 35 (19–66) | 0.13 | 29 (18–69) | 36 (19–66) | 0.10 | 29 (18–69) | 31 (18–62) | 0.74 |
|
| |||||||||||
| Males | n (%) | 45 | 34 (76) | 11 (24) | 0.07 | 33 (73) | 12 (27) | 0.04 | 31 (69) | 14 (31) | 0.83 |
|
| |||||||||||
| Stage | n (%) | 0.18 | 0.32 | 0.45 | |||||||
| ES-F | 31 | 23 (74) | 8 (26) | 23 (74) | 8 (26) | 21 (68) | 10 (32) | ||||
| ES-U | 39 | 34 (87) | 5 (13) | 34 (87) | 5 (13) | 23 (59) | 16 (41) | ||||
| AS | 33 | 29 (88) | 4 (12) | 28 (85) | 6 (15) | 25 (76) | 8 (24) | ||||
|
| |||||||||||
| B symptoms | n (%) | 37 | 33 (89) | 4 (11) | 0.28 | 32 (86) | 5 (14) | 0.59 | 26 (70) | 11 (30) | 0.67 |
|
| |||||||||||
| Bulky disease | n (%) | 48 | 42 (87) | 6 (13) | 0.43 | 42 (87) | 6 (13) | 0.30 | 32 (67) | 16 (33) | >0.99 |
|
| |||||||||||
| Histologic subtype | n (%) | <0.001 | <0.001 | 0.03 | |||||||
| Nodular sclerosis | 91 | 81 (89) | 10 (11) | 80 (88) | 11 (12) | 59 (65) | 32 (35) | ||||
| Mixed cellularity | 9 | 3 (33) | 6 (67) | 3 (33) | 6 (67) | 9 (100) | 0 (0) | ||||
| cHL - nos | 3 | 2 (67) | 1 (33) | 2 (67) | 1 (33) | 1 (33) | 2 (67) | ||||
|
| |||||||||||
| EBV | n (%) | <0.001 | <0.001 | 0.59 | |||||||
| Negative | 85 | 77 (91) | 8 (9) | 76 (89) | 9 (11) | 58 (68) | 27 (32) | ||||
| Positive | 18 | 9 (50) | 9 (50) | 9 (50) | 9 (50) | 11 (61) | 7 (39) | ||||
ES-F: early-stage favorable; ES-U: early-stage unfavorable; AS: advanced stage; cHL - nos: classical Hodgkin lymphoma - not otherwise specified